<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T08:07:30Z</responseDate><request verb="GetRecord" identifier="oai:digital.lib.washington.edu:1773/38596" metadataPrefix="dim">https://digital.lib.washington.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:digital.lib.washington.edu:1773/38596</identifier><datestamp>2026-02-16T02:34:12Z</datestamp><setSpec>com_1773_4888</setSpec><setSpec>col_1773_4904</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Maly, Dustin J</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" authority="2191c200-092f-4276-9c9a-de15bee737aa" confidence="300">Trevillian, Bridget Marley</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2017-05-16T22:12:09Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2017-05-16</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2016-12</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">Trevillian_washington_0250E_16768.pdf</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/1773/38596</dim:field>
   <dim:field mdschema="dc" element="description">Thesis (Ph.D.)--University of Washington, 2016-12</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Chapter 1: Development of a Small Molecule Regulated Cre Recombinase Our lab has previously developed a chemical genetic method for controlling signaling enzymes with a small molecule. In this method, the endogenous regulatory domains of an enzyme of interest are replaced with a protein-protein interaction that acts as an artificial regulatory domain. This synthetic enzyme can be controlled by a potent, selective and cell permeable small molecule that disrupts the protein-protein interaction that serves as the artificial regulatory domain. Cre (Causes Recombination) Recombinase is a site-specific tyrosine recombinase from bacteriophage P1. Cre is commonly used to facilitate conditional knock-in, knock-out and inversion studies is mammals8. This chapter describes the development of a Cre Recombinase whose activity can be controlled in cells with the small molecule-regulated switch that we previously reported. Our small molecule-regulated Cre Recombinase allows rapid, reversible, and dose-dependent activation of Cre recombinase and has the potential to be used to conditionally activate or inactivate gene expression in vivo. Applications of our small molecule-regulated Cre Recombinase and efforts to determine the mechanism of small molecule regulation are described. Chapter 2: A Chemical-Genetic Strategy for the Investigation of Kinase Non-Catalytic Function using Covalent Conformation-Selective Inhibitors Protein kinases are a large family of >530 signaling proteins that allow a cell to respond appropriately to a variety of external stimuli (Manning et. al. 2002). Most current research on protein kinases focuses on studying their catalytic activity, but recent evidence has shown that the non-catalytic role of kinases–including scaffolding and DNA binding–is essential to cell survival (Rauch et. al 2011). A major challenge in studying the non-catalytic roles of protein kinases is the lack of selective molecular tools for studying this aspect of kinase function. As a result, the non-catalytic functions of most proteins kinases are not well understood. A major focus of research in the field has been development of inhibitors that selectively bind distinct ATP-binding site conformations of kinases. Specifically, Type I inhibitors (Taylor et al, 2011), which bind catalytically active kinases, and type II inhibitors, which bind to catalytically inactive forms of the ATP-binding site (Ranjitkar et al, 2010; Ranjitkar et al, 2014; Seeliger et al, 2009; Okram et al, 2006). In many kinases, the conformation of the ATP-binding site and regulatory domains are allosterically coupled. Stabilizing different ATP-binding site forms with conformation-selective inhibitors has the potential to divergently modulate the non-catalytic roles of protein kinases in the cell (Rauch et al, 2011).  The second half of this thesis describes work analyzing the divergent impacts of conformationally-selective inhibitors on the non-catalytic functions of Src Family Kinases (SFKs) in cells.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="rights">none</dim:field>
   <dim:field mdschema="dc" element="subject">Biological Chemistry</dim:field>
   <dim:field mdschema="dc" element="subject">Chemistry</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other">Chemistry</dim:field>
   <dim:field mdschema="dc" element="title">Development of a Small Molecule Regulated Cre Recombinase and A Chemical-Genetic Strategy for the Investigation of Kinase Non-Catalytic Function using Covalent Conformation-Selective Inhibitors</dim:field>
   <dim:field mdschema="dc" element="type">Thesis</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="terms">Delay release for 1 year -- then make Open Access</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="lift">2018-05-16T22:12:09Z</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>